Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-09-19
2006-09-19
Helms, Larry R. (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007230, C435S023000, C530S350000, C436S064000, C436S501000
Reexamination Certificate
active
07108983
ABSTRACT:
The present invention describes a method for determining whether an individual is likely to suffer from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual.
REFERENCES:
patent: 5324634 (1994-06-01), Zucker
patent: 5356817 (1994-10-01), Cole
patent: 2003/0082652 (2003-05-01), Holten-Andersen et al.
patent: 2004/0105862 (2004-06-01), Pan et al.
patent: 2004/0157278 (2004-08-01), Astle et al.
patent: PA 1999 00476 (1999-04-01), None
patent: 1171771 (2000-10-01), None
patent: 1381631 (2002-10-01), None
patent: 1 382 969 (2004-01-01), None
patent: 0 439 393 (2004-07-01), None
patent: WO 93/20447 (1993-10-01), None
patent: 9738314 (1997-10-01), None
patent: WO 00/20860 (2000-04-01), None
patent: WO 00/62070 (2000-10-01), None
patent: WO 00/62070 (2000-10-01), None
patent: WO 02/44736 (2002-06-01), None
patent: 02/086085 (2002-10-01), None
patent: WO 02/086085 (2002-10-01), None
patent: WO 03/060522 (2003-07-01), None
patent: WO 03/087830 (2003-10-01), None
patent: WO 2004/029627 (2004-04-01), None
patent: WO 2005/010213 (2005-02-01), None
Oberg, A, et al, 2000, Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer, Anticancer Research, vol. 20, No. 2B, pp. 1085-1091.
Holten-Andersen, MN, et al, 2000, High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer, Clinical Cancer Research, vol. 6, No. 11, pp. 4292-4299.
Michael, M, et al, 1999, Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer, Journal of Clinical Oncology, vol. 17, No. 6, pp. 1802-1808.
Pohl, AL, et al, 1994, Neural network evaluation of multiple tumor markers for diagnosis of ovarian cancer (meeting abstract), Non-serial, 3rdInternational Conference of the Mediterranean Society of Tumor Marker Oncology, CANCERLIT Accession No. 95614997.
Ward, AM, 1985, Tumour Markers, Developmental Oncology, vol. 21, pp. 90-106.
Genesis Group Associates, Inc., 1997, New tests improve breast cancer prognosis, Genesis Report-Dx, vol. 6, No. 3, NLDB Accession No. 97:320100.
Berend, KR, et al, 1998, Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis, and survival, Journal of Bone and Joint Surgery, American Volume, vol. 80, No. 1, pp. 11-17.
Ikebe, T, et al, 1999, Gelatinolytic activity of matrix metalloproteinase in tumor tissues correlates with the invasiveness of oral cancer, Clinical and Experimental Metastasis, vol. 17, No. 4, p. 315-323.
Arnold, SM, et al, 1999, Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in paired primary tumors and brain metastases, Clinical Cancer Research, vol. 5, No. 12, pp. 4028-4033.
McKay, JA, et al, 2000, Application of the enrichment approach to identify putative markers of response to 5-fluorouracil therapy in advanced colorectal carcinomas, International Journal of Oncology, vol. 17, No. 1, pp. 153-158.
Aoudjit, F, et al, 1999, Gelatinase B (MMP—9), but not its inhibitor (TIMP-1), dictates the growth rate of experimental thymic lymphoma, International Journal of Cancer, vol. 82, No. 5, pp. 743-747.
Zhou, W, et al, 1998, Identifying markers for pancreatic cancer by gene expression analysis, Cancer Epidemiology, Biomarkers and Prevention, vol. 7, No. 2, pp. 109-112.
Tockman, MS, et al, 1992, Considerations in bringing a cancer biomarker to clinical application, Cancer Research, vol. 52, Suppl., pp. 2711s-2718s.
Holten-Andersen MN, et al. Clin Chem. 2002; 48 (8): 1305-13.
Plumpton TA, et al. Clinica Chemica Acta. 1995; 240: 137-54.
International Search Report for International Application No. PCT/DK 00/0170 dated Aug. 10, 2000.
Garrett c. Durkan et al., “Prognostic Significance of Matrix Metalloproteinase-1 and Tissue inhibitor of Metalloproteinase-1 in Voided Urine Samples with Patients with Transitional Cell Carcinoma of the Bladder”, Clinical Cancer Research, vol. 7, Nov. 2001, pp. 3450-3456, XP002268767.
Patent Abstracts of Japan, vol. 1996, No. 9, Sep. 30, 1996 & JP 08-136548A (Morinaga & Co Ltd).
Vincent Leroy et al., “Circulating Matrix Metalloproteinases 1, 2, 9 and Their Inhibitors TIMP-1 and TIMP-2 as Serum Markers of Liver Fibrosis With Chronic Hepatitis C: Comparison with PIIINP and Hyaluronic Acid” American Journal of Gastroenterology, 2004 (pp. 271-279).
Simpson RA, et al. Colorectal Dis. 2000; 2: 100-5.
Pellegrini P, et al. Cancer Immunol Immunother. Sep. 2000; 49 (7): 388:94.
Matsuura E, et al. J. Neurol Sci. 2000; 173:45-52.
Jinnin M, et al. Clin Exp Rheumatol. Jul.-Aug. 2002; 20 (4): 539-42.
Katoh N, et al. Clin Exp Immunol. 2002 127:283-8.
Tsavellas G, et al. Br J Surg. Oct. 2001; 88 (10): 1307-20.
Liefers GJ, et al. Histopathology. May 1999; 34 (5): 385-90.
Lacroix J, et al. Sem Surg Oncol. 2001; 20:252-64.
Calaluce R, et al. J. Surg Oncol. 1998; 67: 194-202.
Ishida H, et al. Surg Today. 2003; 33 (12): 885-92.
Oberg A, et al. Anticancer Res. Mar.-Apr. 2000; 20 (2B): 1085-91.
Holten-Andersen, Mads N. et al., “Plasma levels of Tissue Inhibitor of Metalloproteinases 1 measured during follow-up of colorectal cancer patients have clinical value in predicting patient outcome,” Proceedings Of The American Association For Cancer Research Annual, vol. 43, Mar. 2002, p. 715 (Abstract).
Takada, N. et al., “Postoperative sequential changes of serum levels of matrix metalloproteinase and tissue inhibitor of metalloproteinase in Japanese patients with the squamous cell carcinoma of esophagus,” Proceedings Of The American Association For Cancer Research Annual, vol. 40, Mar. 1999, p. 346 (Abstract).
Zucker, Stanley et al., “Plasma assay of gelatinase B: Tissue inhibitor of metalloproteinase complexes in cancer,” Cancer (Philadelphia), vol. 76, No. 4, 1995, pp. 700-708.
Holten-Andersen, Mads N. et al., “Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity on patients with colon cancer,” Clinical Cancer Research: An Official Journal Of The American Association For Cancer Research, vol. 8, No. 1, Jan. 2002, pp. 156-164.
Zhou, W. et al., “Identifying markers for pancreatic cancer by gene expression analysis,” Database Medline [Online], Abstract of Cancer Epidemiology, Biomarkers & Prevention: A Publication Of The American Association For Cancer Research, Cosponsored by The American Society Of Preventive Oncology, Feb. 1998, vol. 7, No. 2, 2 pages, (Abstract).
National Library of Medicine, PubMed Website. “Serum levels of a tissue inhibitor of metalloproteinases-1 (TIMP-1) in bladder cancer patients”, Naruo S et al., Int J Urol, vol. 1, No. 3 Sep. 1994, pp. 238-231. see abstract.
National Library of Medicine, PubMed Website, “Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation”, Hennet P. et al., APMIS , vol. 109, No. 1, Jan. 1999, pp. 111-119. see abstract.
Patent Abstracts of Japan, JP8136548 A, Morinaga, May 31, 1996.
Dialog Information Services, File t59, Cancerlit, acession No. 93691448, Guillem JG et al., “Evaluation of tissue inhibitor of metalloproteinase-1 (TIMP-1) as a prognostic marker of human colorectal cancer invation”, Proc Annu Meet Am Assoc Cancer Res: 34:A466 1993.
Dialog Information Services, File 159, Cancerlit, accession No. 96647008, “Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases” Clin Cancer Res; 1(8): 899-906 1995 Zeng Z et al.
Mads N. Holten-Andersen et al., “Measurement of the Noncomplexed Free Fraction of Tissue Inhibitor of Metalloproteinases I in Plasma by Immunoassay”,Clinical Chemistry48:8, 1305-1313 (2002).
Mads N. Holten-Andersen et
Brünner Nils
Christensen Ib Jarle
Holten-Andersen Mads N.
Jorgen Nielsen Hans
Stephens Ross W.
Helms Larry R.
Hunton & Williams LLP
Rawlings Stephen L.
Rigshospitalet
LandOfFree
Tissue inhibitor of matrix metalloproteinases type-1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tissue inhibitor of matrix metalloproteinases type-1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue inhibitor of matrix metalloproteinases type-1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3554911